AgomAb Therapeutics Completes Euros 21m Series A Financing
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: Business Wire
EUR 21m Series A secured with international investor syndicate co-led by V-Bio Ventures (Belgium) and Advent France Biotechnology (France), and joined by Boehringer Ingelheim Venture Fund (Germany), Omnes (France) and Pontifax (Israel) Senior appointments announced including Tim Knotnerus as Chief Executive Officer, Torsten Dreier as Chief Development Officer, and John Haurum as Chairman of the Board of Directors Exclusive license for HGF-mimetic SIMPLE Antibodies™, developed as a value-creating partnership with argenx SE (Netherlands) under its Innovative Access Program GHENT, Belgium--(BUSINESS WIRE)-- AgomAb Therapeutics N.V. (‘AgomAb’), a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured EUR 21m in a Series A financing round from a strong intern
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.MarketBeat
- argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseGlobeNewswire
- argenx Announces Annual General Meeting of Shareholders on May 7, 2024GlobeNewswire
- argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Scotiabank from $402.00 to $408.00. They now have a "sector perform" rating on the stock.MarketBeat
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaGlobeNewswire
ARGX
Earnings
- 2/29/24 - Miss
ARGX
Sec Filings
- 3/27/24 - Form 6-K
- 3/27/24 - Form 6-K
- 3/26/24 - Form 6-K
- ARGX's page on the SEC website